Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance – Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – BOSTON, Mass., April 25, 2025 — Ironwood P ...

Shares of Ironwood Pharmaceuticals (IRWD) plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel syndrome (“SBS”) with intestinal failure (“IF”).Following the recent discussion with the FDA, management noted that a confirmatory phase III study will be required to seek approval of apraglutide for patients with SBS-IF and dependent on parenteral support.Simultaneously, IRWD is looking to explore alternat ...

Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.Ironwood has engaged Goldman Sachs Group Inc GS to explore strategic alternatives.Apraglutide is a once-weekly, long-acting synthetic GLP-2 analog with the potential to treat rare gastrointestinal diseases.In preparation for the new drug application (NDA) submission, pharmacokinetic analysis indicat ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.I’ve always been intrigued by Ironwood Pharmaceuticals (NASDAQ: IRWD ), dating back about seven years ago when I kept a close eye on the company as I was trying to figure out if Synergy Pharmaceuticals could eventually getHe is the leader of the investin ...

Ironwood Pharmaceuticals (IRWD) reported adjusted earnings of 2 cents per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of 10 cents. The company had recorded break-even earnings in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter were $90.5 million, which also missed the Zacks Consensus Estimate of $92 million. The top line decreased almost 23% year over year due to the decrease in collaborative arrange ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome ...

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80%. A quarter ago, it was expected that this drugmaker would post earnings of $0.09 per share when it actually produced earnings of $0.02, delivering a surprise of -77.78%.Over the last four quarters, ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – BOSTON, Mass., February 27, 2025 — Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter ...

Ironwood Pharmaceuticals, Inc. (IRWD) announced that it has initiated the rolling new drug application (“NDA”) submission for the next-generation GLP-2 analog, apraglutide, for treating short bowel syndrome (“SBS”) patients who are dependent on parenteral support.The NDA filing is expected to be completed in the third quarter of 2025.The company also announced a corporate restructuring and a strategic reorganization. IRWD has decided to reduce its current workforce by almost 50% to achieve long-term growth. ...

The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off the second phase of a landmark process that aims to make costly medications more affordable for seniors. Topping the list are Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product in the talks since they all share the same active ingredient: semaglutide. Those ...